

## JHEP Reports

### CTAT methods

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

--

#### 1.1 Antibodies

Name	Citation	Supplier	Cat no.	Clone no.
Human suPAR ELISA	-	ViroGates, Birkerød, Denmark	A001	n.a.
Anti-uPA Receptor antibody	-	Abcam, Cambridge, UK	ab218106	n.a

#### 1.2 Cell lines

Name	Citation	Supplier	Cat no.	Passage no.	Authentication test method
-	-	-	-	-	-

#### 1.3 Organisms

Name	Citation	Supplier	Strain	Sex	Age	Overall n number
-	-	-	-	-	-	-

#### 1.4 Sequence based reagents

Name	Sequence	Supplier
-	-	-

#### 1.5 Biological samples

Description	Source	Identifier
Human CCA tumor tissue	University Hospital RWTH Aachen, Institute of Pathology	Prof. Dr. Thomas Longerich
Human CCA serum samples	University Hospital RWTH Aachen, Department of Surgery	Prof. Dr. Ulf P. Neumann

## 1.6 Deposited data

Name of repository	Identifier	Link
-	-	-

## 1.7 Software

Software name	Manufacturer	Version
Excel	Microsoft	Microsoft Office Professional 2010 Version: 14.0.6023.1000
Word	Microsoft	Microsoft Office Professional 2010 Version: 14.0.6023.1000
SPSS Statistics	IBM	Version: 23.0.0.0

## 1.8 Other (e.g. drugs, proteins, vectors etc.)

-	-	-
---	---	---

## 1.9 Please provide the details of the corresponding methods author for the manuscript:

**Tom Luedde, MD/PhD**  
 Professor of Medicine  
 Division of Gastroenterology, Hepatology and Hepatobiliary Oncology  
 University Hospital RWTH Aachen  
 Pauwelsstrasse 30, 52074 Aachen, Germany  
 Email: [tluedde@ukaachen.de](mailto:tluedde@ukaachen.de)  
 Fax: +49-(0)241-8082455

## 2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

Not applicable